Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?
Keywords:
tildrakizumab 200 mg, psoriasis, Anti-IL-23, psoriasis treatment, obesity, dose escalationAbstract
Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life.
Objectives: The study aimed to identify patient characteristics that indicate the initiation of a 200-mg dosage of tildrakizumab in a real-world setting, focusing on factors that enhance treatment efficacy and safety.
Methods: This prospective study included 54 adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg from March 2023 to March 2024 across 13 Italian Dermatology Units. Data collected included demographics, disease duration, comorbidities, and previous treatments. PASI, BSA, and DLQI scores were recorded at baseline, week 4, 16, and 28. Safety was assessed through adverse event reporting. Univariate analysis was performed to identify baseline characteristics significantly associated with achieving PASI ≤ 5 at week 16.
Results: Significant reductions in PASI scores were observed at week 4 (9 ± 6.9, p<0.001), with further improvements at weeks 16 (3.9 ± 4.2, p<0.001) and 28 (2.9 ± 4.4, p<0.001). Univariate analysis showed that obese patients (BMI > 30) had higher odds (OR = 4.333, p < 0.05) of achieving PASI ≤ 5. Longer disease duration and starting with a 100 mg dose also correlated with better outcomes. The safety profile was favorable, with minimal adverse events reported.
Conclusions: Tildrakizumab 200 mg is effective and safe for moderate-to-severe psoriasis, particularly in obese patients. These findings support its use as a long-term treatment option.
References
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. PMID: 23014338.
Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766. DOI: 10.1016/S0140-6736(21)00184-7. PMID: 33515492.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul 21;370(9583):263-271. doi: 10.1016/S0140-6736(07)61128-3. PMID: 17658397.
Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014 Apr 17;7:119-32. doi: 10.2147/CCID.S44843. PMID: 24790463; PMCID: PMC4000177.
Di Brizzi EV, Rocco A, Babino G, et al. Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs. Biomedicines. 2022 Nov 18;10(11):2968. doi: 10.3390/biomedicines10112968. PMID: 36428539; PMCID: PMC9687727.
Visconti MJ, Bashyam AM, Feldman SR. Treatment decisions in psoriasis. J Comp Eff Res. 2019 Sep;8(12):947-949. doi: 10.2217/cer-2019-0090. Epub 2019 Sep 12. PMID: 31512930.
Ahmad Fadzil MH, Ihtatho D, Mohd Affandi A, Hussein SH. Objective assessment of psoriasis erythema for PASI scoring. J Med Eng Technol. 2009;33(7):516-24. doi: 10.1080/07434610902744074. PMID: 19639508.
Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16. PMID: 26573299; PMCID: PMC4706579.
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (ReSURFACE 1 and ReSURFACE 2): Results from two randomised con- trolled, phase 3 trials. Lancet. 2017;390(10091):276-288. DOI: 10.1016/S0140-6736(17)31279-5. PMID: 28596043.
Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Dermatol Pract Concept. 2023 Oct 1;13(4):e2023215. doi: 10.5826/dpc.1304a215. PMID: 37992389; PMCID: PMC10656146.
EMA. Ilumetri [Internet]. European Medicines Agency. 2018. https://www.ema.europa.eu/en/ medicines/human/EPAR/ilumetri. Accessed 10 Dec 2021.
Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Derma- tol. 2015;173(4):930–939. DOI: 10.1111/bjd.13932. PMID: 26042589.
Kokolakis G, Kreis G, Falqués M, et al. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers. Dermatol Ther (Heidelb). 2022 Sep;12(9):2135-2144. doi: 10.1007/s13555-022-00789-9. Epub 2022 Aug 19. PMID: 35984626; PMCID: PMC9388364.
Gargiulo L, Ibba L, Cascio Ingurgio R, et al. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis). J Dermatolog Treat. 2024 Dec;35(1):2350760. doi: 10.1080/09546634.2024.2350760. Epub 2024 May 7. PMID: 38714323.
Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28. PMID: 29532693.
Assan F, Tubach F, Arlegui H, et al. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. Dermatology. 2021;237(3):338-346. doi: 10.1159/000513398. Epub 2021 Feb 3. PMID: 33535213.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11. PMID: 30017705.
Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2016;232(6):633-639. doi: 10.1159/000455840. Epub 2017 Feb 23. PMID: 28226326.
Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2022 Jul 6;23(14):7499. doi: 10.3390/ijms23147499. PMID: 35886846; PMCID: PMC9321445.
Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw (Online). 2017 Aug 24;71(1):761-772. doi: 10.5604/01.3001.0010.3854. PMID: 28894050.
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207. Epub 2019 Feb 22. PMID: 30794469.
Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. Curr Obes Rep. 2020 Sep;9(3):165-178. doi: 10.1007/s13679-020-00380-3. PMID: 32418186.
Yıldırım FE, Hapa FA. Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. J Dermatolog Treat. 2022 May;33(3):1531-1537. doi: 10.1080/09546634.2020.1839009. Epub 2020 Nov 1. PMID: 33074062.
Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014 Jan-Feb;105(1):31-44. English, Spanish. doi: 10.1016/j.ad.2012.08.003. Epub 2012 Nov 23. PMID: 23177976.
Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11. doi: 10.1111/j.1468-3083.2011.04065.x. Epub 2011 Apr 15. PMID: 21492252.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, Francesco Cusano, Rocco De Pasquale , Valeria Falcomatà, Caterina Foti, Claudia Giofrè, Emanuela Gubinelli, Giampiero Mazzocchetti, Massimiliano Nicolini, Giovanni Palazzo, Leonardo Pescitelli, Rosa Valentina Puca, Oriele Sarno, Anna Balato
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.